Render Target: STATIC
Render Timestamp: 2024-11-15T10:06:35.543Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-09-20 06:23:32.032
Product last modified at: 2024-08-30T22:45:07.431Z
1% for the planet logo
PDP - Template Name: Chemical Modulators
PDP - Template ID: *******c501c72

BC-11-38 #82556

    Product Information

    Product Usage Information

    BC-11-38 is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 1.10 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.

    Storage

    Store lyophilized at room temperature, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Product Description

    Molecular Weight 304.4 g/mol
    Purity >98%
    Molecular Formula C15H16N2OS2
    CAS 68770-80-9
    Solubility Soluble in DMSO at 50 mg/mL or ethanol at 14 mg/mL.

    Background

    The small-molecule BC-11-38 is an inhibitor of dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11 (PDE11), which catalyzes hydrolysis of the second messengers cyclic guanosine 3', 5'-monophosphate (cGMP) and cyclic AMP (cAMP) in intracellular signaling regulation. BC-11-38 is a selective and potent inhibitor of PDE11, displaying IC50 values of less than 330 nM for PDE11 and a greater than 100-fold selectivity for PDE11 relative to other PDE isozymes. BC-11-38 treatment of human adrenocortical cells inhibited PDE11 and resulted in increased cAMP levels, cAMP-dependent protein kinase (PKA) activity, and cortisol production (1,2). At the time of its identification, BC-11-38 was thought of as a potential therapeutic target for the treatment of renal insufficiency (3).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.